



## Neuland Q2FY22 income at Rs.258.1 crore, up 6.7%

**EBITDA at Rs. 43.1 crore, up 4.1%**

Hyderabad, India, October 29, 2021 - Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the second quarter and half year ended September 30, 2021.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“Our GDS business delivered growth led by performance of the specialty segment. We believe that our sustainable operations amid these uncertain times demonstrates our execution capabilities. We are confident that our strategy of delivering differentiated products to our customers is a competitive advantage which will maximize value for all our stakeholders.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added *“Our teams are working closely together to ensure smooth execution of CMS projects. We are happy to see this reflected in the increase in revenues from Development projects. We look forward to commercialising these projects in the future.”*

### Financial Summary

Particulars	Rs. crore							
	Q2FY22	Q1FY22	QoQ Growth (%)	Q2FY21	YoY Growth (%)	H1FY22	H1FY21	YoY Growth (%)
Total Income	258.1	202.9	27.2%	242.0	6.7%	461.1	448.1	2.9%
EBITDA	43.1	27.7	55.8%	41.4	4.1%	70.7	75.8	(6.7%)
EBITDA margin (%)	16.7%	13.6%	310 bps	17.1%	(40) bps	15.3%	16.9%	(160) bps
PAT	20.3	8.6	135.1%	21.3	(4.7)%	29.0	36.4	(20.4)%
PAT margin (%)	7.9%	4.3%	360 bps	8.8%	(90) bps	6.3%	8.1%	(180) bps
EPS (Basic) Rs.	15.8	6.7	135.1%	16.63	(4.7)%	22.6	28.37	(20.4)%

### Q2 FY22 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST on Friday, October 29, 2021** where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the Zoom link below:

[Zoom Link](#)



Please note that the transcript of the conference call will be uploaded on the company website in due course.

## About Neuland Laboratories Limited

For over 37 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 898+ Regulatory filings in the US (57 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit [www.NeulandLabs.com](http://www.NeulandLabs.com).

**If you have any questions or require further information, please feel free to contact**

***IR Department at Neuland***

***Tel: +91 40 6761 1600***

***Email: [ir@neulandlabs.com](mailto:ir@neulandlabs.com)***

***Diwakar Pingle, Christensen***

***Email: [dpingle@christensenir.com](mailto:dpingle@christensenir.com)***